Sofia Steinmetz de Souza, Milena Dutra Pierezan, Guilherme de Souza Hassemer, C. M. Lima, J. De Dea Lindner, Marília Miotto, S. Verruck
{"title":"Effect of Prebiotics and Synbiotics Carried by Food over Irritable Bowel Syndrome Symptoms: A Systematic Review","authors":"Sofia Steinmetz de Souza, Milena Dutra Pierezan, Guilherme de Souza Hassemer, C. M. Lima, J. De Dea Lindner, Marília Miotto, S. Verruck","doi":"10.3390/dairy3010012","DOIUrl":null,"url":null,"abstract":"Irritable bowel syndrome (IBS) is a chronic condition that affects 11.2% of the world’s population. The management of gut microbiota using probiotic and synbiotic agents might be a valid alternative to assist in the treatment of IBS. The focus of this study was to evaluate the effects of prebiotic and synbiotic compounds carried by different foods on major symptoms of IBS through a systematic literature review. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and LILACS were accessed during July 2021. The studies included in this review were the ones that tested volunteers older than 16 years of age and were conducted using a randomized, controlled clinical trial. The risk of bias was assessed by using the Cochrane risk-of-bias tool for randomized trials (RoB2). Furthermore, the data found were qualitatively evaluated due to the studies’ differences. Two papers were able to fit the criteria, with a total sample size of 280 participants. No datum was found regarding the use of prebiotics in the treatment of IBS. Synbiotic agents, however, had a positive effect on gastrointestinal symptoms and the participants’ overall bowel satisfaction; however, it was not possible to reach a consensus on which effects. Further studies regarding the use of synbiotics and prebiotics must be carried out to determine which effects are the most significant in the treatment of IBS.","PeriodicalId":11001,"journal":{"name":"Dairy Science & Technology","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dairy Science & Technology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/dairy3010012","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Agricultural and Biological Sciences","Score":null,"Total":0}
引用次数: 2
Abstract
Irritable bowel syndrome (IBS) is a chronic condition that affects 11.2% of the world’s population. The management of gut microbiota using probiotic and synbiotic agents might be a valid alternative to assist in the treatment of IBS. The focus of this study was to evaluate the effects of prebiotic and synbiotic compounds carried by different foods on major symptoms of IBS through a systematic literature review. MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and LILACS were accessed during July 2021. The studies included in this review were the ones that tested volunteers older than 16 years of age and were conducted using a randomized, controlled clinical trial. The risk of bias was assessed by using the Cochrane risk-of-bias tool for randomized trials (RoB2). Furthermore, the data found were qualitatively evaluated due to the studies’ differences. Two papers were able to fit the criteria, with a total sample size of 280 participants. No datum was found regarding the use of prebiotics in the treatment of IBS. Synbiotic agents, however, had a positive effect on gastrointestinal symptoms and the participants’ overall bowel satisfaction; however, it was not possible to reach a consensus on which effects. Further studies regarding the use of synbiotics and prebiotics must be carried out to determine which effects are the most significant in the treatment of IBS.
肠易激综合征(IBS)是一种慢性疾病,影响着世界11.2%的人口。使用益生菌和合成制剂管理肠道微生物群可能是辅助肠易激综合征治疗的有效替代方法。本研究的重点是通过系统的文献综述,评价不同食物携带的益生元和合成化合物对肠易激综合征主要症状的影响。在2021年7月访问了MEDLINE、EMBASE、Cochrane Central Register of Controlled Trials和LILACS。本综述中包括的研究是对年龄在16岁以上的志愿者进行测试,并采用随机对照临床试验进行的。使用Cochrane随机试验风险偏倚工具(RoB2)评估偏倚风险。此外,由于研究的差异,对发现的数据进行了定性评估。两篇论文符合标准,总样本量为280人。没有发现关于使用益生元治疗肠易激综合征的数据。然而,合成制剂对胃肠道症状和参与者的总体肠道满意度有积极影响;但是,不可能就哪些影响达成一致意见。关于使用合成菌和益生元的进一步研究必须进行,以确定哪种效果在治疗肠易激综合征中最显著。